



About 10% to 15% of ovarian cancers are linked to genetic abnormalities, including breast cancer susceptibility gene
(BRCA) mutations, and Lynch syndrome. The aim of this work was to provide comprehensive and updated review of
this distinct type of ovarian cancer that carries genetic alterations in relation to its pathology, prevention, prognosis,
and management. Genetic ovarian cancer has a distinct pathologic and molecular biology features. BRCA1 and
BRCA2 mutation ovarian cancers are most likely to be high-grade serous adenocarcinomas. Many BRCA1-mutated
tumors harbor a mutant p53 gene, c-myc overexpression, and epidermal growth factor receptor overexpression.
Clinically, genetic ovarian cancer presents at a younger age than sporadic ovarian cancer. For prevention, risk-
reduction salpingo-oophorectomy is an effective tool. Chemoprevention by oral contraceptives may represent an
option. A recent study demonstrates improved progression-free survival and overall survival in patients whose ovarian
cancer displays BRCA1 and BRCA2mutation, relative to those who have normal BRCA1 and BRCA2 function. Recent
management advances include PARP (poly[adenosine diphosphate {ADP}eribose] polymerases) inhibitors. Signiﬁcant
progress has been recently made in elucidating the role of BRCA1 and BRCA2 mutation and Lynch syndrome on
ovarian cancer prognosis and management.
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Ovarian cancer represents the sixth most common cancer among
women worldwide. It accounts for 4% of all new cancer cases.
Despite recent advances in diagnosis and management, more than
60% of patients present with stage III or stage IV. The 5-year
overall survival (OS) remains around 47%, and nearly 50% of pa-
tients die from this cancer.1-3
About 10% to 15% of ovarian cancers are linked to genetic
abnormalities. Breast cancer susceptibility gene (BRCA) germline
mutations account for 85% of all hereditary ovarian cancer.4,5
Genetic ovarian cancer appears to be heterogeneous diseases in
comparison with sporadic cancer ovary. It is characterized by vari-
able clinical courses, associate with other cancers, and includes
different molecular pathways.6
The aim of this work was to provide comprehensive and updated
review of this distinct type of ovarian cancer that carries genetic
alterations in relation to its pathology, prevention, prognosis, and
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Genetic ovarian cancer is part of several cancer syndromes. The
most commonly associated syndromes are BRCA1 and BRCA2
mutation syndromes. BRCA1 and BRCA2 germline mutations ac-
count for approximately 65% to 85% of the genetic alterations
associated with genetic ovarian cancer.7
Both BRCA1 and BRCA2 are transmitted as autosomal dominant
trait. Certain ethnic groups, eg, Ashkenazi Jews, have the highest
rates of mutation of these genes.
BRCA1 gene is a tumor-suppressor gene, located on 17q21, from
base pair 43,044,294 to base pair 43,125,482. BRCA1 gene mu-
tation is associated with increased risk for breast cancer and ovarian
cancer by 65% to 80% and 45% to 60%, respectively.
BRCA2 gene is another tumor-suppressor gene, located on
13q12.3, from base pair 32,315,479 to base pair 32,399,671.
BRCA2 gene mutation is associated with increased risk for breast
cancer and ovarian cancer by 45% to 60% and 20% to 30%,
respectively (Figure 1).8-10
BRCA1 and BRCA2 gene mutations are associated with other
cancers including contralateral breast cancer (40%), cancer pancreas
(7%), cancer prostate (20%-39%), melanoma (4%), colon cancer
(5%), fallopian tube, peritoneal cancer, male breast cancer
(2%-6.8%), and acute myeloid leukemia.11-13
Genetic ovarian cancer has also been associated with Lynch
syndrome which in the general population occurs in about 1 in
2000 individuals. Lynch syndromeeassociated disease accountsClinical Ovarian and Other Gynecologic Cancer December 2014 - 1
Figure 1 BRCA1 and BRCA2 Gene Location
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2 - Clifor another 10% to 15% risk for developing genetic ovarian
cancer.14
Lynch syndrome is an autosomal dominant syndrome that in-
cludes mutation in 1 of the 4 genes: MLH1, MSH2, MSH6, and
PMS2, with subsequent impairment in mismatch repair.
Lynch syndrome is associated with other cancers apart from
including cancer colon (80%), stomach cancer (11%-19%), hep-
atobiliary cancer (2%-7%), urinary tract cancer (4%-5%), small
bowel cancer (1%-4%), brain tumor (1%-3%), and endometrial
cancer (20%-60%).15,16
Studies showed that ovarian cancer is associated with mutation of
MLH1, MSH2, and MSH6 in 20%, 24%, and 1% of patients,
respectively. Other recent reports noted that MSH2 gene mutation
had nearly twice the incidence rate observed in MLH1 gene
mutation.16,17
Other genetic abnormalities that were associated with ovarian
cancer include Li-Fraumeni syndrome due to p53 mutations,
Cowden syndrome due to PTEN mutations, basal cell nevus
(Gorlin) syndrome, and multiple endocrine neoplasia type 1. They
account for 4% to 5% of genetic ovarian cancer.18
Pathology
Several studies have conﬁrmed the distinct entity of genetic
ovarian cancer from sporadic ovarian cancer.
BRCA1 and BRCA2 mutation ovarian cancers are most likely to
be high-grade serous adenocarcinomas. In a study by Lu et al., more
than 90% of their 48 patients with BRCA1-mutated ovarian cancer
were high-grade serous adenocarcinoma, compared to 50% in pa-
tients without BRCA mutation. The second common pathology is
endometroid carcinoma (10%-14%).6,19,20
Further, a recent study failed to identify the exact site of origin in
BRCA-mutated ovarian cancer. They observed that, in risk-reducing
salpingo-oophorectomy (RRSO) specimens from BRCA mutationnical Ovarian and Other Gynecologic Cancer December 2014carriers, the premalignant lesion was found in the distal, ﬁmbriated
end of the fallopian tube, rather than the ovary.21
For Lynch syndromeeassociated ovarian cancer, the commonest
pathology has been yet determined. Although high-grade serous
carcinoma was the commonest pathology in 2 studies (50% in
both), it was detected only in 25% of the third trial, with endo-
metroid, or mixed serousemucinous pathology, being more
common.6,22
Molecular Biology
Data support for distinct molecular pathways of carcinogenesis
for BRCA1- and BRCA2-mutated ovarian cancer when compared to
sporadic ovarian cancer. However, for Lynch syndromeeassociated
ovarian cancer, the molecular pathways are not yet understood.23
BRCA1 is Implicated in Multiple Cellular Functions
Based on Its Protein Interactions
Many BRCA1-mutated tumors harbor a mutant p53 gene.
Studies suggest that loss of p53 is a programmed hit in the pathway
of BRCA1-mutated tumor development.23
Also, BRCA1 is phosphorylated (activated) mainly by the DNA
damage sensors; the protein kinases mutated in the ataxia telan-
giectasia syndrome, and checkpoint-2, implicating it in the DNA
damage response. However, to date, there are limited data as to
how extent each phosphorylation event affects function of
BRCA1.24
Furthermore, it is believed that BRCA1 modulates transcriptional
control mainly via its interactions with many transcription factors,
including c-Myc. Overexpression of c-Myc has been reported in
30% of BRCA-mutated high-grade ovarian serous adenocarcinomas.
Interestingly, BRCA mutations also disrupt the binding of BRCA1
to the histone deacetylase (HDAC) complex. BRCA1 has 2
opposing roles in chromatin activation; it may recruit HDAC
Mohammed A. Osmancomplexes to speciﬁc promoters to modulate local chromatin
structure, thereby making speciﬁc sites less accessible for transcrip-
tion factors and repressing transcription. Conversely, BRCA1 may
activate transcription by displacing HDAC complexes from speciﬁc
promoters. It is believed that deregulated HDAC activity plays a
role in the carcinogenesis.25,26
Additionally, several studies have implicated BRCA1 in the
regulation of apoptosis after cellular stress and DNA damage.
Conversely, lack of BRCA1 expression diminished the apoptotic
effect. The mechanisms by which BRCA1 induces apoptosis are not
well understood. A correlation between BRCA1 and the anti-
apoptotic BCL2 expression was reported as an explanation.27
Also, the epidermal growth factor receptor (EGFR; also referred
to as HER1) is overexpressed in 30% to 70% of high-grade serous
ovarian carcinomas. Interestingly, increased EGFR signaling is
detected more often in metastases than in primary epithelial
ovarian cancer tumor. HER2/neu is overexpressed in 20% to 30%Figure 2 The Molecular Pathways for Carcinogenesis in Genetic Ovof high-grade serous ovarian carcinomas and rarely in low-grade
and borderline tumors.28
Furthermore, the signiﬁcance of the PI3K/AKT pathway in
ovarian cancer is clearly deﬁned recently. Evidence of deregulation
of the PI3K/AKT signaling pathway in genetic ovarian cancer in-
cludes gain of function mutations and ampliﬁcations of PI3 kinase
genes and mutations of PTEN.29
However, the mutations in the KRAS and BRAF genes are rarely
detected in genetic ovarian cancer as compared with borderline and
low-grade sporadic ovarian cancers (Figure 2).6
PARP Inhibition and BRCA Mutation
DNA repair allows cancer cells to survive the DNA injury posed
by chemotherapy or radiation. Multiple types of DNA repair
mechanisms exist; these include pathways that repair single-strand
breaks and others that repair double-strand breaks including the
nonhomologous end joining and homologous recombinationarian Cancer
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pathway are BRCA1 and BRCA2.
BRCA1 and BRCA2 mutations result in faulty homologous
recombination. This is likely a key step in tumorigenesis in in-
dividuals with BRCA1 and BRCA2 mutations who are predisposed
to the development of ovarian cancer.
Poly(adenosine diphosphate [ADP]eribose) polymerases (PARP)
detect the single-strand breaks that are induced to remove damaged
bases. Speciﬁcally, the loss of PARP function results in the accu-
mulation of single-strand DNA breaks, which are subsequently
converted to double-strand breaks by cellular transcription and
replication. These double-strand breaks, which are typically repaired
by homologous recombination or nonhomologous end joining in
normal cells, would accumulate in BRCA1- and BRCA2-deﬁcient
cells, leading to subsequent cell death.30-32
For Lynch-associated cancer ovary, few molecular pathways have
been reported including the following.
PTEN mutation was found in 14% of endometroid ovarian
cancer. For mixed endometriodeclear cell carcinoma, PTEN mu-
tation was found in 5.5%. PTEN inhibits the AKT signaling
pathway; therefore, with dysfunction of this gene and encoded
protein, proliferation of transformed cells continues unabated.6
Transforming growth factor b receptor II (TGFbR2) may
represent another molecular pathway on the basis of some data from
Lynch-associated cancer colon.6
Clinical Picture
Generally, genetic ovarian cancer occurs at a younger age than spo-
radic ovarian cancer. For BRCA-mutated ovarian cancer, the mean age
at diagnosis is about 50 years (range, 40-60 years), and for those with
Lynch syndrome is about 40 years (range, 31-48 years). The mean age
of onset in women with BRCA1 mutation is signiﬁcantly earlier than
those with BRCA2mutation (aged 45 and 57 years, respectively).33,36
Data suggest that BRCA-mutated ovarian cancers metastasize
more frequently to the viscera, whereas sporadic ovarian cancers
remain conﬁned to the peritoneum. The prognosis for BRCA-
mutated ovarian cancer appears to be somewhat better than that for
sporadic ovarian cancer.33
For Lynch syndromeeassociated ovarian cancer, few data exist to
show the presentation. In a study by Rijcken et al.,34 24 patients were
diagnosed with Lynch-associated ovarian cancer, 83% presented by a
disease conﬁned to the ovary, 42%associatedwithmalignant peritoneal
cytology, and 33% associated with coexisting endometrial carcinomas.
The stage distribution workup is similar to sporadic ovarian
cancer.33
Screening
No effective method for ovarian cancer screening currently exists.
Although some groups recommend transvaginal ultrasound exami-
nations and CA 125 in women with BRCA1 and BRCA2 mutations
and lynch syndrome, the majority of guidelines do not recommend
them because none of them appears to detect ovarian cancer at early
stages or reduce the risk of dying from ovarian cancer.35
Prevention
Nevertheless, in BRCA-mutated carriers, risk-reducing salpingo-
oophorectomy reduces the risk for developing ovarian cancer.nical Ovarian and Other Gynecologic Cancer December 2014However, it cannot completely eliminate that risk. Even studies
showed that carriers of BRCA mutation who underwent prophy-
lactic salpingo-oophorectomy developed peritoneal cancer even after
prophylactic surgery. However, the mortality reduction associated
with this surgery is substantial. A study by Domchek et al.,36
showed that women who underwent bilateral prophylactic
salpingo-oophorectomy had a nearly 80% reduction in risk of dying
from ovarian cancer and a more than 50% reduction in risk of dying
from breast cancer.
For Lynch syndrome carriers, few studies exist to conﬁrm the
efﬁcacy of prophylactic surgery in reducing the risk of ovarian
cancer. The study of Schmeler et al. retrospectively compared 46
Lynch syndrome carriers who had undergone hysterectomy with or
without bilateral salpingo-oophorectomy with 223 Lynch syndrome
carriers who had not undergone hysterectomy. They observed that
none of the 46 carriers who underwent surgery developed ovarian
cancer during an average 20 years, whereas 5.4% of those who did
not have surgery were diagnosed with ovarian cancer during the
same period.37
Timing for Surgery
For BRCA1 and BRCA2 mutations, it is recommended to do the
surgery by the age of 35 years or earlier on completion of family size.
For Lynch syndrome (MSH6 and PMS2), it is advisable by the age
of 30 to 35 years or earlier on completion of the family size.36,37
Chemoprevention
Oral contraceptives including either combined estrogene
progesterone or medroxyprogesterone may lower the risk of
ovarian cancer in women with BRCA1 or BRCA2 mutations. In a
study by McLaughlin et al.,38 the use of oral contraceptives reduced
the risk of ovarian cancer in carriers of BRCA1 and BRCA2 muta-
tions by 44% and 61%, respectively.
For Lynch syndrome, oral contraceptives may also be an effective
chemopreventive agent for reducing the risk of Lynch syndromee
associated ovarian cancer, on the basis of its proven effectiveness
in general population risk (50% risk reduction) and its effectiveness
in reducing the risk of lynch-associated endometrial cancer.39,40
Genetic Counselling
Genetic advice is a mandatory process in genetic ovarian cancer.
It is an essential part in the management of this genetic disease. It
has to be done by genetic professional and it should provide in-
dividuals and families with information on the nature, mode of
inheritance, risk to family members, implications of this genetic
disorder, genetic testing including prenatal testing, and the way to
interpret the results of genetic testing to help them make informed
medical and personal decisions.41
Prognosis
A recent systematic review and meta-analysis demonstrate
improved progression-free survival and overall survival in patients
whose ovarian cancer displays BRCA1 and BRCA2mutations, relative
to those who have normal BRCA1 and BRCA2 functions. Further-
more, studies showed that, BRCA2 mutations are associated with
better response to chemotherapy and longer platinum-free survival
durations than BRCA1 mutations and sporadic ovarian cancer.
Table 1 Clinical Trials of PARP Inhibitors in Ovarian Cancer
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Mohammed A. OsmanBRCA status especially BRCA2 may inﬂuence the choice of
chemotherapy agents for recurrent disease.41,42
For BRCA1 mutation, the situation is more complicated because
mutations at the N-terminal and C-terminal region of the proteins
have opposite association with survival. Further analysis will be
needed to stratify the BRCA1 mutations and their impact on
survival.41,43
For Lynch syndromeeassociated ovarian cancer, few data showed
that it seems to have a better prognosis than sporadic ovarian cancer
and BRCA1 and BRCA2 mutations.44
Management of Genetic Ovarian Cancer
Till now, it applies the same management principles as sporadic
ovarian cancer for both BRCA-mutated and Lynch-associated
ovarian cancer for both early disease and metastatic disease.45Figure 3 Strategies for Therapeutic Intervention Targeting BRCA Ge
Abbreviation: DSBs ¼ double strand breaks.Recent Advances
Recent studies showed that PARP inhibitors have cytotoxic
effects on BRCA1- and BRCA2-mutated cells. Promising results
from clinical trials in BRCA-associated ovarian cancer have been
reported (Table 1).
Furthermore, some preclinical data suggest that BRCA2-mutated
cells respond better to PARP inhibitors than BRCA1-mutated
cells.50 (Figure 3)
Future Perspectives
The differences in survival and chemotherapy responses among
BRCA1 and BRCA2 mutation ovarian cancer may have important
implications for the future of clinical trial designs.50
Also, understanding the homologous recombination pathway
and the impact of mutations in BRCA1 and BRCA2 genes in thatne
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plorations and drug development, especially after considering the
study of Issaeva et al. that found cisplatin-resistant breast cancer
cells with BRCA2 mutations are still sensitive to 6-
thioguanine.51,52
Conclusion
Signiﬁcant progress has been recently made in elucidating the
role of BRCA1 and BRCA2 mutation and Lynch syndrome on
ovarian cancer prognosis and management. BRCA mutation status
will be important marker for treatment guidelines and clinical trial
designs.
Clinical Practice Points
 About 10% to 15% of ovarian cancers are linked to genetic
abnormalities, including breast cancer susceptibility gene
(BRCA) mutations, and Lynch syndrome.
 The aim of this work was to provide comprehensive and updated
review of this distinct type of ovarian cancer that carries genetic
alterations in relation to its pathology, prevention, prognosis, and
management.
 Genetic ovarian cancer has a distinct pathologic and molecular
biology features. BRCA1 and BRCA2 mutation ovarian cancers
are most likely to be high-grade serous adenocarcinomas. Many
BRCA1-mutated tumors harbor a mutant p53 gene, c-myc
overexpression, and epidermal growth factor receptor
overexpression.
 Clinically, genetic ovarian cancer presents at a younger age than
sporadic ovarian cancer. For prevention, risk-reduction salpingo-
oophorectomy is an effective tool. Chemoprevention by oral
contraceptives may represent an option.
 A recent study demonstrates improved progression-free survival
and overall survival in patients whose ovarian cancer displays
BRCA1 and BRCA2 mutation, relative to those who have
normal BRCA1 and BRCA2function.
 Recent management advances include PARP (poly[adenosine
diphosphate {ADP}eribose] polymerases) inhibitors. Signiﬁcant
progress has been recently made in elucidating the role of
BRCA1 and BRCA2 mutation and Lynch syndrome on ovarian
cancer prognosis and management.
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